Ahmedabad, Gujarat, India, April 2025 — Parthiv Mehta has been appointed as Vice President – Rest of Africa & International Fertility at Intas Pharmaceuticals, bringing with him over two decades of diverse experience in pharmaceutical marketing, brand strategy, and international business development. In his new capacity, Parthiv will drive growth across African markets and spearhead the company’s strategic initiatives in the global fertility domain.
Prior to this, Parthiv served at Glenmark Pharmaceuticals in a series of impactful roles, most recently as Head – East Africa, where he led commercial operations and growth strategies across a highly competitive market landscape. His earlier roles at Glenmark as Cluster Head and Head – Marketing for Africa demonstrate his consistent ability to scale brands, penetrate new markets, and manage regional complexities with agility.
Earlier in his career, Parthiv served as Head of the Healthcare Division at Tata International Limited, where he managed operations across Kenya, Uganda, Tanzania, Nigeria, Zambia, Mozambique, and Ghana. His strategic vision was instrumental in building Tata’s pan-African healthcare presence. Before Tata, he contributed significantly to Dr. Reddy’s Laboratories, where he led nephrology and chronic care divisions and managed some of the company’s flagship brands including Omez, Nise, and Stamlo.
Parthiv began his career at GlaxoSmithKline, managing major portfolios in dermatology and nutraceuticals, further laying the groundwork for his expertise in category management and brand development. His deep pan-African market insights, combined with his legacy of performance and leadership, make him a key addition to the Intas Pharmaceuticals executive team as the company advances its global ambitions in specialized therapeutic areas.
Intas Pharmaceuticals is a leading multinational pharmaceutical formulation development, manufacturing, and marketing organization with a global footprint spanning over 85 countries. With over 70% of its revenue derived from international business, Intas operates under the Accord Healthcare brand across the US, EU, Canada, Australia, APAC, CIS, and MENA regions. Ranked 6th in the Indian pharmaceutical market, Intas has established leadership across key therapeutic segments including CNS, Oncology, Cardiology, and Urology. The company is supported by over 23,000 employees and operates 17 world-class R&D and manufacturing facilities accredited by global regulators such as USFDA and EMA.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
